ClinicalTrials.gov
ClinicalTrials.gov Menu

Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes) (RAPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00526552
Recruitment Status : Completed
First Posted : September 10, 2007
Last Update Posted : March 30, 2010
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Condition or disease
Dyslipidemia Diabetes

Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)
Study Start Date : June 2007
Actual Primary Completion Date : August 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Diabetic Mellitus patients with hypercholesteromia in Korean tertiary care centers
Criteria

Inclusion Criteria:

  • Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

    1. Over 18 years of age
    2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion Criteria:

  1. Patients already taking other hyperlipidemic agents
  2. Patients who do not fulfil the indication criteria for statin therapy
  3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00526552


Locations
Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hyunah Caroline Choi AstraZeneca Korea

Additional Information:
ClinicalTrials.gov Identifier: NCT00526552     History of Changes
Other Study ID Numbers: NIS-CKR-CRE-2007/3
First Posted: September 10, 2007    Key Record Dates
Last Update Posted: March 30, 2010
Last Verified: March 2010

Keywords provided by AstraZeneca:
dyslipidemia
rosuvastatin
diabetes
cholesterol
Naturalistic
Observational

Additional relevant MeSH terms:
Diabetes Mellitus
Dyslipidemias
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors